Drugs / CT-2106
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00291785 | Jan 2004 → Aug 2007 | colorectal cancer | CTI BioPharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00291837 | Nov 2004 → Jun 2006 | ovarian cancer | CTI BioPharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-2106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00291785 ↗ |
| Action | Inhibit | “topoisomerase I inhibitors” NCT00291785 ↗ |
| Modality | Other / unclassified | “a camptothecin (CPT) conjugate” NCT00291785 ↗ |